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Cancer and metabolic disorders are associated with an aberrant
activity of the PI(3)K/PTEN/AKT pathway. In liver tumours, this
pathway is activated by loss of function of PTEN [1] or gains of
function of receptor tyrosine kinases and PI(3)K [2].
Binding of growth factors (insulin, IGF, EGF, HGF, FGFb, PDGF,
VEGF) to receptor tyrosine kinases (RTKs) leads to autophosphory-
lation of the receptors. This activates class IA PI(3)K either by direct
docking to the receptor or by binding to the scaffolding adaptors
insulin receptor substrate-1 (IRS-1) and IRS-2. PI(3)K is composed
of a p85 regulatory subunit and a p110 catalytic subunit. The p85
subunit binds, stabilises and inhibits the p110 catalytic subunit
until receptor activation occurs. PI(3)K phosphorylates phosphati-
dylinositol-4,5-bisphosphate (PI(4,5)P2) to generate phosphati-
dylinositol-3-4-5-trisphosphate (PI(3,4,5)P3). PI(3,4,5)P3 recruits
and localises PDK1 andAKT to the inner leaﬂet of the plasmamem-
brane, where PDK1 phosphorylates the activation loop of AKT at
Thr308. Additional phosphorylation on Ser473 by mTOR complex
2 (mTORC2) is necessary to fully activate AKT. Ser473 site can also
be phosphorylated by DNA-PKc and ATM following DNA damage.
In addition to AKT activation, PDK1 also phosphorylates and acti-
vates aPKCs, promoting lipogenesis, inﬂammation and systemic
insulin resistance and decreasing gluconeogenesis. AKT is nega-
tively regulated by dephosphorylation. Protein phosphatase 2A
(PP2A) dephosphorylates AKT on both sites, but particularly at
Thr308. The phosphatase PHLPP directly dephosphorylates the
Ser473 site.
The PI(3)K/AKT pathway is negatively regulated by the phos-
phatase and tensin homolog PTEN. PTEN is a lipid phosphatase
which dephosphorylates the 3-position of PI(3,4,5)P3 to
PI(4,5)P2, terminating signaling downstream of PI(3)K by reduc-
ing the recruitment of PDK1 and AKT to the plasma membrane
and decreasing AKT activity. PI(3,4,5)P3 is also rapidly degraded
at the 5-position by 5-phosphatases (such as SHIP2) forming
PI(3,4)P2.
PTEN expression and activity are regulated by numerous
mechanisms [3]. Expression of PTEN is upregulated by several
transcription factors (Egr1, IGF-2, p53, PPAR-c, Spry2, Atf2, and
c-Myc), whereas other transcription factors negatively regulateJournal of Hepatology 20
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PTEN is also repressed post-transcriptionally by speciﬁc miRNAs
(miR-21, miR-19a, miR-17-92, miR-214, miR-216a and miR-217).
PTEN protein is regulated by several posttranslational modiﬁca-
tions: phosphorylation, acetylation, ubiquitination and the redox
state, which affect PTEN stability, degradation and enzymatic
activity. Unsaturated fatty acids decrease the expression of PTEN.
Phosphorylated and activated AKT disassociates from the
plasma membrane and translocates to different subcellular com-
partments (nucleus, endoplasmic reticulum, Golgi, mitochondria)
where it exerts its biological activities [4] (Fig. 1).
a. AKT increases cell survival by inhibition of apoptosis
through phosphorylation of FOXOs, BAD, MDM2, GSK3
and YAP.
b. AKT promotes cell growth through activation of mTOR
complex 1 (mTORC1). Activated mTORC1 phosphorylates
downstream targets such as 4E-BP1 and S6K1. These
effects result in the stimulation of translation initiation
and ribosome biogenesis. Importantly, active S6K1 can
phosphorylate serine residues on IRS-1, targeting IRS-1
for degradation and resulting as a negative feedback mech-
anism to attenuate PI(3)K/AKT signaling and leading to
decrease in insulin sensitivity.
c. AKT increases cell proliferation, mainly by regulation of
FOXOs and p53.
d. AKTplays an important role in angiogenesis, either through
direct phosphorylation and activation of endothelial nitric
oxide synthase (eNOS), or through increased production of
hypoxia-inducible factor a (HIF1a and HIF2a) via mTORC1.
e. AKT is implicated in the regulation of glucose and lipid
metabolism. AKT stimulates glucose uptake in response
to insulin through stimulation of Glut4 translocation to
the plasma membrane. Glucose uptake may also be stimu-
lated by increased expression of Glut1 through mTORC1
activation. Glucose is converted into glucose-6-phosphate
by hexokinases, which are activated and stabilised by AKT.
AKT induces glycogen synthesis by removing the inhibitory
effects of GSK3 on glycogen synthase. GSK3 inactivation by
AKT also induces lipogenesis through SREBP-1c activation.
Through FOXOs inhibition, AKT decreases gluconeogenesis
and triglycerides metabolism. Importantly, increased lipid
synthesis by SREBP-1c also occurs throughmTORC1 activa-
tion, but it remains unclear whether the downstream effect
of mTORC1 on SREBP-1c is distinct of S6K1 [5,6].11 vol. 54 j 1317–1319
Fig. 1. The phosphatase PHLPP directly dephosphorylates the Ser473 site.
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JOURNAL OF HEPATOLOGYThe pathway can be over-activated in HCC by an enhanced
stimulation of receptor tyrosine kinases particularly the IGF
receptor and EGFR [2]. PTEN is a tumour suppressor whose gene
is mutated in 5% of HCCs and its expression reduced in nearly half
of all HCCs. PTEN expression can also be downregulated directly
by the HBX protein in HBV-infected patients [2]. Rare somatic
mutations in the PI(3)K catalytic a gene PIK3CA may activate its
kinase function. p85a expression is signiﬁcantly reduced in many
human cancers including HCC [7]. The levels of the phosphory-
lated form of mTOR have been shown to be elevated in 15% of
HCC and the levels of total S6K1 in 45% of cases [2]. PTEN expres-
sion is decreased by unsaturated fatty acid, through a mechanism
involving the activation of mTOR and NFjB, resulting in miR-21
upregulation and PTEN mRNA degradation [8,9]. PTEN downreg-
ulation and deletion in the liver induces steatosis development,
but the mechanisms for this remain unclear [8,10].Conﬂict of interest
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